nach oben

Erschienen in:

01.03.2005 | Original Research Article

Cytochrome P450 Polymorphisms in Geriatric Patients

Impact on Adverse Drug Reactions — A Pilot Study

verfasst von: Dr Tobias Egger, Harald Dormann, Gabi Ahne, Andreas Pahl, Ulrich Runge, Tanya Azaz-Livshits, Antje Neubert, Manfred Criegee-Rieck, Karl G. Gassmann, Kay Brune

Erschienen in: Drugs & Aging | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

Up to 23% of the population, depending on their ethnic background, has genetically determined differences in the metabolism of drugs by the cytochrome P450 (CYP) enzymes CYP2C9, CYP2C19 and CYP2D6. The aim of this survey was to determine the relationship between genetical polymorphisms in these CYP enzymes and adverse drug reactions (ADRs) in geriatric patients.

Study design

In a prospective 6-month cohort study of 243 patients in a geriatric rehabilitation ward, mean age 80.2 ± 7.7 years, ADRs were identified by intensive monitoring by a pharmacoepidemiological team, consisting of pharmacists and physicians. 125 out of these 243 patients were genotyped cross-sectionally for polymorphisms of CYP2C9, CYP2C19 and CYP2D6 by the TaqMan-polymerase chain reaction. The main outcome measures were the prevalence of genetical polymorphisms and the patients’ risk for developing an ADR as related to the genotype.

Results

Patients received an average of 14.2 drugs during hospitalisation which led to 251 ADRs in the whole cohort and 149 ADRs in the cross-sectional genotyping study. Genotype frequencies of CYP2C9 enzyme were 25.9% (n = 29) intermediate metabolisers (IMs) and 2.7% (n = 3) poor metabolisers (PMs). For the enzyme CYP2C19, 26.8% (n = 33) IMs and 0.8% (n = 1) PMs were detected. For the enzyme CYP2D6, 24.1% (n = 26) IMs and 3.7% (n = 4) PMs were found in the analysed patient population. In total, 61.6% (n = 77) of genotyped patients experienced mutations in at least one of the three cytochrome enzymes. The ADR rate did not differ significantly between patients with genetic mutations and wild-type genotype patients. Moreover, only eight out of 40 ADRs which were associated with drugs metabolised by CYP2C9, CYP2C19 or CYP2D6 were detected in patients with IM genotype and none in patients with PM genotype.

Conclusion

In this investigation geriatric patients showed a high rate of ADRs. However, no association between the ADR rate and the patients’ genotype could be detected, which most likely was a result of the small number of patient samples analysed.

Although prophylactic genotyping would have not prevented ADRs in this pilot study, physicians nevertheless have to be aware of potential genetic mutations in patients with polypharmacy.

Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324(6): 377–84PubMedCrossRef

Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8(6): 289–94PubMedCrossRef

Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200–5PubMedCrossRef

Levy M, Azaz-Livshits T, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: implementation. Eur J Clin Pharmacol 1999; 54(11): 887–92PubMedCrossRef

Mannesse CK, Derkx FH, de Ridder MA, et al. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 2000; 29(1): 35–9PubMedCrossRef

Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003; 20(10): 769–76PubMedCrossRef

Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001; 161(13): 1629–34PubMedCrossRef

Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39(11): 1093–9PubMed

Dormann H, Krebs S, Muth-Selbach U, et al. Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk? Aliment Pharmacol Ther 2001; 15(2): 171–80PubMedCrossRef

10.

Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997; 45(8): 945–8PubMed

11.

Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286(18): 2270–9PubMedCrossRef

12.

Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353(9154): 717–9PubMedCrossRef

13.

Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356(9242): 1667–71PubMedCrossRef

14.

Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000; 10(1): 27–34PubMedCrossRef

15.

Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis and management. Lancet 2000; 356(9237): 1255–9PubMedCrossRef

16.

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239–45PubMedCrossRef

17.

Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22(2): 161–8PubMedCrossRef

18.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions [letter]. Hosp Pharm 1992; 27(6): 538PubMed

19.

Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60(2): 284–95PubMed

20.

Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7(1): 59–64PubMedCrossRef

21.

Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54(10): 1257–70PubMedCrossRef

22.

Flockhart DA. Cytochrome P450 drug interaction table [online]. Available from URL: http://medicine.iupui.edu/flockhart/ [Accessed 2002 Dec 2]

23.

Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003; 348(6): 538–49PubMedCrossRef

24.

Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. BMJ 2000; 320(7240): 987–90PubMedCrossRef

25.

Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348(6): 529–37PubMedCrossRef

26.

Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20(8): 342–9PubMedCrossRef

27.

Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants: the role of the CYP family of enzymes. Mutat Res 2001; 482(1–2): 11–9PubMed

28.

Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41(12): 913–58PubMedCrossRef

29.

Clark D, Morgan A, Hananeia L, et al. Drug metabolism ge notypes and their association with adverse drug reactions in selected populations: a pilot study of methodology. Pharmacoepidemiol Drug Saf 2000; 9: 393–400PubMedCrossRef

30.

Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001; 21(2): 235–42PubMedCrossRef

31.

Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72(4): 429–37PubMedCrossRef

32.

Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72(4): 438–52PubMedCrossRef

33.

Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants: a pilot study. Clin Pharmacol Ther 2004; 75(5): 386–93PubMedCrossRef

34.

Tamminga WJ, Wemer J, Oosterhuis B, et al. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. Eur J Clin Pharmacol 2003; 59(1): 57–64PubMed

35.

Hippius M, Buchardt C, Farker K, et al. Adverse drug reaction monitoring in Jena: relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions. Exp Toxicol Pathol 2003; 54(5–6): 417–21PubMed

Titel: Cytochrome P450 Polymorphisms in Geriatric Patients
Impact on Adverse Drug Reactions — A Pilot Study
verfasst von: Dr Tobias Egger
Harald Dormann
Gabi Ahne
Andreas Pahl
Ulrich Runge
Tanya Azaz-Livshits
Antje Neubert
Manfred Criegee-Rieck
Karl G. Gassmann
Kay Brune
Publikationsdatum: 01.03.2005
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 3/2005
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200522030-00007

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background and objective

Study design

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2005

Chronic Actinic Dermatitis in the Elderly

Cyclo-Oxygenase-2 Inhibitors

Assessing Medication Adherence in the Elderly

Management of Diabetes Mellitus Medications in the Nursing Home

Atypical Antipsychotics for Nursing Home Patients